TrialCurveSCANDIUM: reconstructed Kaplan–Meier curves
Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | J Clin Oncol. 2023 Mar 20;41(16):3042–50. doi: 10.1200/JCO.22.01705 |
|---|---|
| DOI | 10.1200/JCO.22.01705 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival (blinded central review) — ITT population
From figure panel A · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Allocated = IHP 7.4 months; Allocated = control 3.2 months. Survival at 12 months: Allocated = IHP 32%. Hazard ratio Allocated = IHP vs Allocated = control 0.21 (95% CI 0.13–0.36).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Allocated = IHP | 43 | 38 | 7.4 |
| Allocated = control | 44 | 43 | 3.2 |
- Allocated = IHP vs Allocated = control: reconstructed HR 0.21 (95% CI 0.13–0.36)
Landmark survival (reconstructed)
| Time | Allocated = IHP | Allocated = control |
|---|---|---|
| 6 mo | 57.0% | 10.0% |
| 12 mo | 31.8% | — |
| 18 mo | 15.9% | — |
| 24 mo | 5.3% | — |
Hepatic progression-free survival (blinded central review) — ITT population
From figure panel B · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Allocated = IHP 8.3 months; Allocated = control 3.4 months. Survival at 12 months: Allocated = IHP 42%; Allocated = control 2%. Hazard ratio Allocated = IHP vs Allocated = control 0.22 (95% CI 0.13–0.38).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Allocated = IHP | 43 | 35 | 8.3 |
| Allocated = control | 44 | 42 | 3.4 |
- Allocated = IHP vs Allocated = control: reconstructed HR 0.22 (95% CI 0.13–0.38)
Landmark survival (reconstructed)
| Time | Allocated = IHP | Allocated = control |
|---|---|---|
| 6 mo | 61.7% | 14.7% |
| 12 mo | 41.7% | 2.4% |
| 18 mo | 27.1% | — |
| 24 mo | 6.8% | — |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- MIND-DC: Overall survival; Recurrence-free survival
- RELATIVITY-098: Distant metastasis-free survival (DMFS); Overall survival; Recurrence-free survival (RFS)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials